• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vedolizumab for the Induction of Remission in Treatment-refractory Microscopic Colitis in a Pediatric Patient.

作者信息

Wenzel Amanda A, Strople Jennifer, Melin-Aldana Hector, Brown Jeffrey B

机构信息

Division of Gastroenterology, Hepatology and Nutrition.

Department of Pathology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.

出版信息

J Pediatr Gastroenterol Nutr. 2020 Jul;71(1):e47-e48. doi: 10.1097/MPG.0000000000002739.

DOI:10.1097/MPG.0000000000002739
PMID:32304548
Abstract
摘要

相似文献

1
Vedolizumab for the Induction of Remission in Treatment-refractory Microscopic Colitis in a Pediatric Patient.维多珠单抗用于诱导一名儿科难治性显微镜下结肠炎患者的缓解
J Pediatr Gastroenterol Nutr. 2020 Jul;71(1):e47-e48. doi: 10.1097/MPG.0000000000002739.
2
Vedolizumab-Induced Remission in 3 Patients With Refractory Microscopic Colitis: A Tertiary Care Center Case Series.维多珠单抗诱导3例难治性显微镜下结肠炎缓解：一家三级医疗中心的病例系列
Inflamm Bowel Dis. 2019 Jul 17;25(8):e97. doi: 10.1093/ibd/izz042.
3
Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.维多珠单抗用于诱导和维持溃疡性结肠炎缓解：一项Cochrane系统评价与Meta分析
Inflamm Bowel Dis. 2015 May;21(5):1151-9. doi: 10.1097/MIB.0000000000000396.
4
Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.抗肿瘤坏死因子药物与维多珠单抗治疗溃疡性结肠炎的疗效比较
Eur J Gastroenterol Hepatol. 2019 Jun;31(6):661-667. doi: 10.1097/MEG.0000000000001395.
5
Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.维多珠单抗对难治性溃疡性结肠炎儿童抗TNF治疗无效者的疗效。
Acta Paediatr. 2019 Jul;108(7):1359-1360. doi: 10.1111/apa.14765. Epub 2019 Mar 21.
6
Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.维多珠单抗治疗儿童炎症性肠病有效性的多中心经验
Inflamm Bowel Dis. 2016 Sep;22(9):2121-6. doi: 10.1097/MIB.0000000000000865.
7
Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.维多珠单抗成功治疗一名16岁难治性溃疡性结肠炎男孩。
J Crohns Colitis. 2016 Mar;10(3):373-4. doi: 10.1093/ecco-jcc/jjv205. Epub 2015 Nov 15.
8
Real-world evidence for vedolizumab: Understanding the landscape.
J Gastroenterol Hepatol. 2018 Sep;33 Suppl 3:28-29. doi: 10.1111/jgh.14433.
9
Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.致编辑的信：溃疡性结肠炎临床缓解期患者从维多珠单抗静脉制剂转换为皮下制剂：SVEDO研究，一项炎症性肠病全球研究。
Dig Liver Dis. 2024 Apr;56(4):716-717. doi: 10.1016/j.dld.2024.01.187. Epub 2024 Feb 3.
10
Vedolizumab in Refractory Microscopic Colitis: An International Case Series.维得利珠单抗治疗难治性显微镜下结肠炎：一项国际病例系列研究。
J Crohns Colitis. 2019 Mar 26;13(3):337-340. doi: 10.1093/ecco-jcc/jjy169.

引用本文的文献

1
Clinicopathologic Characterization of Lymphocytic Colitis in the Pediatric Population.儿科淋巴细胞性结肠炎的临床病理特征。
Pediatr Dev Pathol. 2024 Mar-Apr;27(2):156-168. doi: 10.1177/10935266231215117. Epub 2023 Dec 31.
2
Microscopic Colitis: A Review Article.显微镜下结肠炎：一篇综述文章。
Cureus. 2023 Oct 16;15(10):e47150. doi: 10.7759/cureus.47150. eCollection 2023 Oct.
3
Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis.维多珠单抗可阻断微小性结肠炎中α4β7整合素介导的T细胞与黏膜地址素细胞黏附分子-1的黏附。
Therap Adv Gastroenterol. 2022 Jun 28;15:17562848221098899. doi: 10.1177/17562848221098899. eCollection 2022.
4
Diagnosis and Management of Microscopic Colitis in Pediatric Patients.儿童显微镜结肠炎的诊断和治疗。
Paediatr Drugs. 2022 May;24(3):217-233. doi: 10.1007/s40272-022-00504-3. Epub 2022 May 2.